OBJECTIVE To prepare a new type of hyaluronic acid-decenylsuccinic anhydride (HA-DSA) nanomicelles loaded with plumbagin (PLB),and to study their quality and in vitro drug release. METHODS Firstly,the drug-loaded material HA-DSA was synthesized, and then the formulation process of PLB-HA-DSA was optimized by Box-Behnken response surface and the in vitro release of PLB-HA-DSA was evaluated by dialysis method and the optimal equation was fitted. RESULTS The optimal formulation process of PLB-HA-DSA was as follows: organic phase-aqueous phase(1∶20),drug:material ratio(1∶11). PLB-HA-DSA was spherical with a particle size of (110.71±2.03) nm, a Zeta potential of (-42.12±2.34) mV,an encapsulation efficiency of (92.12±0.06)%, and a drug load of (5.68±0.06)%. In the in vitro release experiment,the cumulative release degree of PLB-HA-DSA was significantly lower than that of the API. CONCLUSION PLB-HA-DSA nanomicelles are successfully prepared, which could retard the release of PLB in vitro and have a certain sustained release effect.
Key words
plumbagin /
HA-DSA micelle /
Box Behnken response surface optimization /
in vitro release /
nanomicelle
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] YIN Z, ZHANG J, CHEN L, et al. Research progress on the anticancer effect and mechanism of action of plum bagasse glycoside[J]. Biomed Res Int, 2020, 2020:6940953.
[2] LIU C M, HUANG X C, DU B. Experimental study on the mechanism of Plumbagin regulating ROS inhibition of NLRP3 inflammasome to alleviate IgA renal injury[J]. Chin J Clin Anato, 2020, 38(3):308-313.
[3] HAN X, BI X, GUO T, et al. Nanoparticle co delivery of Plumbagin and Dihydrotanshinone can reverse immunosuppressive TME in liver cancer[J]. Controlled Public J, 2022, 348:250-263.
[4] QAIS F A, KHAN M S, AHMAD I, et al. The virulence and biofilm of Plumbagin inhibiting quorum sensing regulation in Gram negative bacteria: in vitro and computer studies[J]. Biofouling, 2021, 37(7):724-739.
[5] YANG F, HOU Q, LI N, et al. Plumbagin inhibits colon cancer cell proliferation and promotes apoptosis through the CXCL8/PI3K/AKT glycolytic pathway[J]. Mod Oncol Med, 2023, 31 (3): 411-416.
[6] SON T G, CAMANDOLA S, ARUMUGAM T V, et al. Plumbagin, a novel Nrf 2/ARE activator, protects against cerebral ischemia[J]. J Neurochem, 2010, 112(5):1316-1326.
[7] RAVINDRA K C,SELVI B R,ARIF M,et al. Inhibition of lysine acetyltransferaseKAT 3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin[J]. Biol Chem,2009,284(36):24453-24464.
[8] LAI L, LIU J, ZHAI D, et al. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2[J]. Br J Pharmacol, 2012, 165(4):1084-1096.
[9] WU B H, YANG H Y, SUN J, et al. Research progress on hyaluronic acid modified anti-tumor drugs[J]. Chem World, 2020(61):662-668.
[10] LIU Y, CAI Y, HE C, et al. Research progress on anticancer properties and pharmaceutical applications of plumbagin[J]. Am J Tradit Chin Med, 2017, 45(3):423-441
[11] PEI Q, HU X, LIU S, et al. Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma[J]. J Controlled Release, 2017, 254:23-33.
[12] MEDINA O P, ZHU Y,KAIREMO K. Targeted liposomal drug delivery in cancer[J]. Curr Pharm Des, 2004, 10(24):2981-2989.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(1672 KB)
